博安生物 港股通 空最新增减持 (2026-01-27) 官网 ( 06955.hk) | 152.30 | 2.33 | 0% | 上市时间2022-12-30股价8.33港币涨跌幅-2.69%成交金额2,820.87万港币换手率0.55%市值51.84亿港币H股市值51.84亿港币总股本6.22亿H股本6.22亿每手股数200上市至今年化投资收益率-24.48%港股通持仓占H股比例21.82% (11.72亿港币2026-01-28) 累计做空占H股比例0.34% (1,857.15万港币2026-01-23) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 66.68 | 市净率 | 5.06 | 股息率 | 0.31% | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 备注 (3): | 双击编辑备注 |
博安生物(06955) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 余家林 | Independent Non Executive Director | 2022-12-02 | -- | |
| 2 | 戴繼雄 | Independent Non Executive Director - A/F | 2022-03-25 | -- | |
| 3 | 史錄文 | Independent Non Executive Director | 2022-03-25 | -- | |
| 4 | 陳杰 | Non Executive Director | 2021-01-25 | 2023-12-12 | |
| 5 | 姜華 | Executive Director | Chairman, CEO | 2020-06-22 | -- |
| 6 | 李莉 | Non Executive Director | 2020-06-22 | -- | |
| 7 | 劉元沖 | Non Executive Director | 2020-06-22 | -- | |
| 8 | 李又欣 | Non Executive Director | 2020-06-22 | 2023-02-12 | |
| 9 | 竇昌林 | Executive Director | 2019-11-16 | -- |